Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three months ended on March 31, 2017 and for the three and six months ended June 30, 2017 have been prepared with all due care and attention (having regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent with those adopted for the preparation of the audited financial statements of the Company and its consolidated subsidiaries for the financial year ended December 31, 2016 and the corresponding interim results of the Company and its consolidated subsidiaries published in the immediately preceding financial year.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Duggan Robert W), Securities Purchase Agreement (Pulse Biosciences, Inc.)
Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three months ended on March 31, 2017 and for the three and six months ended June 30, 2017 2021 have been prepared with all due care and attention (having regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent with those adopted for the preparation of the audited financial statements of the Company and its consolidated subsidiaries for the financial year ended December 31, 2016 2020 and the corresponding interim results of the Company and its consolidated subsidiaries published in the immediately preceding financial year.
Appears in 1 contract
Samples: Securities Purchase Agreement (Pulse Biosciences, Inc.)
Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three months ended on March 31, 2017 and for the three and six months ended June 30, 2017 2023 have been prepared with all due care and attention (having regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent with those adopted for in the preparation of the audited financial statements of the Company and its consolidated subsidiaries for the financial fiscal year ended December 31, 2016 and the corresponding interim results of the Company and its consolidated subsidiaries published in the immediately preceding financial year2022.
Appears in 1 contract
Samples: Securities Purchase Agreement (Summit Therapeutics Inc.)
Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three months ended on March 31, 2017 and for 2016, the three and six months ended June 30, 2017 2016 and the three and nine months ended September 30, 2016 have been prepared with all due care and attention (having regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent with those adopted for the preparation of the audited financial statements of the Company and its consolidated subsidiaries for the financial year ended December 31, 2016 and the corresponding interim results of the Company and its consolidated subsidiaries published in the immediately preceding financial year.
Appears in 1 contract
Samples: Securities Purchase Agreement (Pulse Biosciences, Inc.)
Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three months ended on March 31April 30, 2017 2019 and for the three and six months ended June 30July 31, 2017 2019 have been prepared with all due care and attention (having regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent with those adopted for in the preparation of the audited financial statements of the Company and its consolidated subsidiaries for the financial year ended December January 31, 2016 2019 and the corresponding interim results of the Company and its consolidated subsidiaries published in the immediately preceding financial year, except as otherwise disclosed therein.
Appears in 1 contract
Samples: Securities Purchase Agreement (Summit Therapeutics PLC)
Interim Financials. The published interim results of the Company and its consolidated subsidiaries for the three months ended on March 31April 30, 2017 and for 2018, the three and six months ended June 30July 31, 2017 2018 and the three and nine months ended October 31, 2018 have been prepared with all due care and attention (having regard to the fact that the results were made publicly available) and on accounting bases and assumptions consistent with those adopted for in the preparation of the audited financial statements of the Company and its consolidated subsidiaries for the financial year ended December January 31, 2016 2018 and the corresponding interim results of the Company and its consolidated subsidiaries published in the immediately preceding financial year.
Appears in 1 contract
Samples: Securities Purchase Agreement (Summit Therapeutics PLC)